A once-a-day pill has nearly doubled survival for patients with advanced pancreatic cancer in a large clinical trial, a rare bright spot against one of the deadliest common cancers. According to UCHealth, the drug daraxonrasib increased median survival from 6.7 months to 13.2 months in a 500-person study of people whose disease had already been treated.
Pancreatic cancer has long resisted the advances that transformed the outlook for other tumors, in part because it is often caught late and grows in ways that shrug off standard treatments. Against that backdrop, a trial showing a clear survival gain is the kind of result oncologists watch closely, because meaningful progress in this disease has been so hard to come by.
How the drug works
Daraxonrasib is designed to block the growth-driving proteins made by RAS genes, which are mutated in a large share of pancreatic tumors and have long been considered nearly impossible to target with medicine. By interfering with that signaling, the pill aims to slow or halt tumor growth in a disease that has resisted most treatment advances.
RAS mutations have been called “undruggable” for decades, a reputation earned by the difficulty of designing molecules that can shut them down. A drug that can interfere with RAS signaling in patients therefore represents a scientific milestone as much as a clinical one, opening a target that had frustrated researchers across many cancer types, not just pancreatic.
What the trial found
In the Phase 3 results, the drug reduced the risk of death for patients with metastatic pancreatic cancer by about 60%, according to researchers at Northwestern involved in reporting the data. For a cancer where survival is usually measured in months, doubling median survival and cutting the death rate by more than half is a meaningful shift.
Phase 3 is the stage at which a treatment is tested against the current standard in a large group of patients, so a strong result there carries more weight than earlier, smaller studies. The magnitude of the benefit — roughly doubling median survival — is substantial in a disease where incremental gains are the norm and where many promising drugs have failed to move the needle at all.
Why the results carry weight
Pancreatic cancer is notorious because it is often diagnosed late and responds poorly to existing therapies. A drug that extends life in patients who have already exhausted other options addresses exactly the population with the fewest choices. The findings drew significant attention in the oncology community, though as with any single trial, longer follow-up and regulatory review will shape how widely the treatment is ultimately used.
The patients in the study had already been treated, meaning their cancer had progressed despite prior therapy — the hardest group to help. Extending survival in that setting is precisely what makes the result notable. Regulators will now weigh the full data, and longer follow-up will clarify how durable the benefit is, but the trial has already reframed expectations for a cancer that rarely offers good news.
This article was researched with the help of AI, with human editors creating the final content.
